Axitinib: a review in advanced renal cell carcinoma.

about

Blocking fibrotic signaling in fibroblasts from patients with carpal tunnel syndrome.Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer.

P2860

Q39179076-3F67D4E9-DD55-4B1B-B0C9-0BBD25134823 Q54976476-1C54C27B-9AD4-4D85-ADDB-4AFCAA89E316

P2860

Axitinib: a review in advanced renal cell carcinoma.

Item

http://www.wikidata.org/entity/Q38612808

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Axitinib: a review in advanced renal cell carcinoma.

@en

type

Item

label

Axitinib: a review in advanced renal cell carcinoma.

@en

prefLabel

Axitinib: a review in advanced renal cell carcinoma.

@en

P1476

Axitinib: a review in advanced renal cell carcinoma.

@en

P2860

Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.

Novel approaches in the therapy of metastatic renal cell carcinoma.

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

P2888

s40265-015-0483-x

P304

1903-1913

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-015-0483-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gillian M Keating

P577

2015-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1051386665

http://www.w3.org/2001/XMLSchema#string

P698

26487541

http://www.w3.org/2001/XMLSchema#string

Axitinib: a review in advanced renal cell carcinoma.

about

P2860

P2860

Axitinib: a review in advanced renal cell carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698